Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC).

The Research Domain Criteria (RDoC) initiative aims to organize research according to domains of brain function. Dysfunction within these domains leads to psychopathology that is classically measured with rating scales. Examining the correspondence between the specific measures assessed within rating scales and RDoC domains is necessary to assess the needs for new RDoC-focused scales. Such RDoC-focused scales have the potential of allowing translation of this work into the clinical domain of measuring psychopathology and designing treatment. Here, we describe an initial qualitative assessment by a group of 10 clinician-scientists of the alignment between RDoC domains and the items within five commonly used rating scales. In this commentary, we report limited correspondence and make recommendations for future work needed to address these limitations.
Competing Interests: DISCLOSURES: Dr. Citrome has served as consultant for AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva, and Continuing Medical Education (CME) activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies; owns stocks (small number of shares of common stock) in Bristol-Myers Squibb, Eli Lilly, Johson & Johnson, Merck, Pfizer purchased over 10 years ago, stock options: Reviva; and received royalties from Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics). Dr. Abi-Dargham has received consulting fees and/or honoraria from Sunovion, Otsuka, Merck, and Intracellular Therapies; she holds stock options in Systems 1 Bio and in Terran Biosciences. Dr. Bilder has received consulting fees and/or honoraria from Acadia; Atai Life Sciences; Institute of Digital Media and Child Development, Inc.; Otsuka; ThinkNow, Inc.; and VeraSci. Dr. Dunlop has received research support from Acadia, Compass, Aptinyx, National Institute of Mental Health (NIMH), Sage, and Takeda, and has served as a consultant to Greenwich Biosciences, Myriad Neuroscience, Otsuka, Sage, and Sophren Therapeutics. Dr. Duffy was an employee of Otsuka Continued on page 27. Continued from page 26. Development and Commercialization when this project was conducted. Dr. Harvey has received consulting fees or travel reimbursements from Acadia, Alkermes, Bio Excel, Boehringer Ingelheim, Minerva, Regeneron, and Sunovion during the past year; he has signed contracts but received no compensation to date from Karuna and Takeda; he receives royalties from the Brief Assessment of Cognition in Schizophrenia (Owned by Verasci); he is chief scientific officer of i-Function, Inc.; he had a research grant from Takeda and the Stanley Medical Research Foundation. Dr. Pizzagalli has received funding from NIMH, Brain and Behavior Research Foundation, the Dana Foundation, and Millennium Pharmaceuticals; consulting fees from Albright Stonebridge Group, Neumora Therapeutics (former BlackThorn Therapeutics), Boehringer Ingelheim, Compass Pathways, Concert Pharmaceuticals, Engrail Therapeutics, Neurocrine Biosciences, Neuroscience Software, Otsuka, and Takeda; one honorarium from Alkermes; honoraria from the Psychonomic Society for his Editor-in-Chief role of Cognitive, Affective and Behavioral Neuroscience; stock options from Neumora Therapeutics (former BlackThorn Therapeutics), Compass Pathways, Neuroscience Software. Dr. Tamminga has served as an advisor for Karuna Therapeutics and KyNexis, a consultant to Astellas, and Sunovion and serves on a Merck Data Safety Monitoring Board (DSMB), in addition to holding Karuna stock options. Dr. McIntyre has received research grant support from Canadian Institutes of Health Research (CIHR)/ Global Alliance for Chronic Diseases (GACD)/Chinese National Natural Research Foundation; he has received speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris Eisai, Minerva, Intra-Cellular, Abbvie; he is CEO of Champignon. Dr. Kane has received consulting fees and/or honoraria for lectures from Alkermes, Dainippon Sumitomo, Intracellular Therapies, Janssen, LB Pharma, Lundbeck, Merck, Neurocrine, Otsuka, Roche, Saladex, Sunovion and Teva; he is a shareholder in LB Pharma and The Vanguard Research Group.
(Copyright © 2022. Matrix Medical Communications. All rights reserved.)